My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 302

    1.

    Factors that impact symptomatic diabetic peripheral neuropathy in placebo-administered patients from two 1-year clinical trials.

    Tesfaye S, Tandan R, Bastyr EJ 3rd, Kles KA, Skljarevski V, Price KL; Ruboxistaurin Study Group.

    Diabetes Care. 2007 Oct;30(10):2626-32. Epub 2007 Jul 10.PMID: 17623822 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial.

    Vinik AI, Bril V, Kempler P, Litchy WJ, Tesfaye S, Price KL, Bastyr EJ 3rd; MBBQ Study Group.

    Clin Ther. 2005 Aug;27(8):1164-80.PMID: 16199243 [PubMed - indexed for MEDLINE]Related articles

    3.

    Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy.

    Bastyr EJ 3rd, Price KL, Bril V; MBBQ Study Group.

    Clin Ther. 2005 Aug;27(8):1278-94.PMID: 16199253 [PubMed - indexed for MEDLINE]Related articles

    4.

    Endothelial and neural regulation of skin microvascular blood flow in patients with diabetic peripheral neuropathy: effect of treatment with the isoform-specific protein kinase C beta inhibitor, ruboxistaurin.

    Brooks B, Delaney-Robinson C, Molyneaux L, Yue DK.

    J Diabetes Complications. 2008 Mar-Apr;22(2):88-95.PMID: 18280438 [PubMed - indexed for MEDLINE]Related articles

    5.

    A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy.

    Casellini CM, Barlow PM, Rice AL, Casey M, Simmons K, Pittenger G, Bastyr EJ 3rd, Wolka AM, Vinik AI.

    Diabetes Care. 2007 Apr;30(4):896-902.PMID: 17392551 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy.

    Reljanovic M, Reichel G, Rett K, Lobisch M, Schuette K, Möller W, Tritschler HJ, Mehnert H.

    Free Radic Res. 1999 Sep;31(3):171-9.PMID: 10499773 [PubMed - indexed for MEDLINE]Related articles

    7.

    Effects of sorbinil therapy in diabetic patients with painful peripheral neuropathy and autonomic neuropathy.

    Jaspan JB, Herold K, Bartkus C.

    Am J Med. 1985 Nov 15;79(5A):24-37.PMID: 3000176 [PubMed - indexed for MEDLINE]Related articles

    8.

    Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial.

    Arezzo JC, Rosenstock J, Lamoreaux L, Pauer L.

    BMC Neurol. 2008 Sep 16;8:33.PMID: 18796160 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort.

    Dyck PJ, Davies JL, Litchy WJ, O'Brien PC.

    Neurology. 1997 Jul;49(1):229-39.PMID: 9222195 [PubMed - indexed for MEDLINE]Related articles

    10.

    Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group.

    Apfel SC, Schwartz S, Adornato BT, Freeman R, Biton V, Rendell M, Vinik A, Giuliani M, Stevens JC, Barbano R, Dyck PJ.

    JAMA. 2000 Nov 1;284(17):2215-21.PMID: 11056593 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes.

    Jaspan JB, Towle VL, Maselli R, Herold K.

    Metabolism. 1986 Apr;35(4 Suppl 1):83-92.PMID: 3083212 [PubMed - indexed for MEDLINE]Related articles

    12.

    Challenges in design of multicenter trials: end points assessed longitudinally for change and monotonicity.

    Dyck PJ, Norell JE, Tritschler H, Schuette K, Samigullin R, Ziegler D, Bastyr EJ 3rd, Litchy WJ, O'Brien PC.

    Diabetes Care. 2007 Oct;30(10):2619-25. Epub 2007 May 18.PMID: 17513707 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    A double blind placebo controlled trial of mixed gangliosides in diabetic peripheral and autonomic neuropathy.

    Abraham RR, Abraham RM, Wynn V.

    Adv Exp Med Biol. 1984;174:607-24.PMID: 6331138 [PubMed - indexed for MEDLINE]Related articles

    14.

    The effect of gamma-linolenic acid on human diabetic peripheral neuropathy: a double-blind placebo-controlled trial.

    Jamal GA, Carmichael H.

    Diabet Med. 1990 May;7(4):319-23.PMID: 2159860 [PubMed - indexed for MEDLINE]Related articles

    15.

    Amelioration of sensory nerve dysfunction by C-Peptide in patients with type 1 diabetes.

    Ekberg K, Brismar T, Johansson BL, Jonsson B, Lindström P, Wahren J.

    Diabetes. 2003 Feb;52(2):536-41.PMID: 12540632 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study.

    Hotta N, Toyota T, Matsuoka K, Shigeta Y, Kikkawa R, Kaneko T, Takahashi A, Sugimura K, Koike Y, Ishii J, Sakamoto N; SNK-860 Diabetic Neuropathy Study Group.

    Diabetes Care. 2001 Oct;24(10):1776-82. Erratum in: Diabetes Care 2002 Feb;25(2):413-4. PMID: 11574441 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis.

    Ziegler D, Nowak H, Kempler P, Vargha P, Low PA.

    Diabet Med. 2004 Feb;21(2):114-21.PMID: 14984445 [PubMed - indexed for MEDLINE]Related articles

    18.

    Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial.

    Malik RA, Williamson S, Abbott C, Carrington AL, Iqbal J, Schady W, Boulton AJ.

    Lancet. 1998 Dec 19-26;352(9145):1978-81.PMID: 9872248 [PubMed - indexed for MEDLINE]Related articles

    19.

    Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients.

    Ziegler D, Movsesyan L, Mankovsky B, Gurieva I, Abylaiuly Z, Strokov I.

    Diabetes Care. 2009 Aug;32(8):1479-84. Epub 2009 May 26.PMID: 19470838 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Sural sensory action potential identifies diabetic peripheral neuropathy responders to therapy.

    Vinik AI, Bril V, Litchy WJ, Price KL, Bastyr EJ 3rd; MBBQ Study Group.

    Muscle Nerve. 2005 Nov;32(5):619-25.PMID: 16116628 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity